Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4101174 · 1 trial · 14 indications
Number of participants with dose-limiting toxicities (DLTs)
Number of participants with DLTs
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| LY4101174 (Dose-escalation, Cohort A1) | EXPERIMENTAL | Escalating doses of LY4101174 administered intravenously (IV). |
| LY4101174 (Dose-optimization, Cohort A2) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of LY4101174 administered IV. |
| LY4101174 (Dose-expansion, Cohort B1, B2, C1-C5) | EXPERIMENTAL | LY4101174 administered IV. |
| Name | Type | Description |
|---|---|---|
| LY4101174 | DRUG | Intravenous |
Inclusion Criteria: * Have one of the following solid tumor cancers: * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinom...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LY4101174 is an investigational small molecule being studied for the treatment of recurrent, advanced, or metastatic solid tumors. The Phase 1 trial enrolls adults with several tumor types, including urinary bladder cancer, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer, head and neck squamous cell carcinoma, prostate cancer, and renal pelvis cancer.
LY4101174 targets Nectin-4, a cell surface protein. Nectin-4 is a member of the nectin family of adhesion molecules and is expressed in a range of solid tumors. By binding this target, LY4101174 is designed to act on cancer cells that express Nectin-4.
LY4101174 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating the compound in solid tumors.
LY4101174 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The ongoing study is a Phase 1 trial in participants with recurrent, advanced, or metastatic solid tumors.
LY4101174 is being evaluated in the Phase 1 trial NCT06238479, titled A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors. The trial has an enrollment of 490 participants, is active but not recruiting, and is conducted in the United States, Australia, Belgium, China, France, Japan, and Spain.